Welcome to our dedicated page for Regen Biopharma SEC filings (Ticker: RGBPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regen BioPharma PFD A (RGBPP) SEC filings page aggregates regulatory documents for Regen BioPharma, Inc., a Nevada‑incorporated biotechnology company trading on the OTC Pink marketplace under RGBP and RGBPP. These filings provide detailed insight into the company’s capital structure, financing activities, and progress as it develops immunology and immunotherapy programs such as HemaXellerate.
Regen BioPharma’s recent Form 8‑K reports describe unregistered sales of equity securities, including Tier 2 Regulation A offerings and issuances under Section 4(a)(2) of the Securities Act of 1933. The filings specify the number of common shares issued, the cash consideration received, and instances where shares were issued to satisfy principal and accrued interest on convertible indebtedness. They also note that certain proceeds are allocated to working capital and that shares are sold directly through company management without underwriters or commissions.
Through this page, users can access Regen BioPharma’s SEC submissions associated with both its common and preferred equity, including RGBPP. Filings such as 8‑K, and, where available, periodic reports like 10‑K and 10‑Q, outline key information on the company’s financial condition, risk factors, and business description, including its focus on cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs for cancer and autoimmune disorders.
Stock Titan enhances these documents with AI‑powered summaries that highlight the most important points in lengthy filings, helping readers quickly understand items such as new share issuances, changes in capital structure, and material events. Real‑time updates from the SEC’s EDGAR system ensure that new Regen BioPharma filings appear promptly, while dedicated views for insider‑related forms like Form 4, and for annual and quarterly reports, allow investors to review trading by company insiders, compensation disclosures, and detailed financial and operational data with simplified explanations.
Regen Biopharma, Inc. is an early-stage Nevada biotech focused on regenerative medicine and immuno-oncology, with no clinical trials yet started and no conclusions of efficacy for its product candidates. The company is developing several NR2F6‑targeted programs, including HemaXellerate for severe aplastic anemia, dCellVax and tCellVax cell therapies, DiffronC and DuraCar for solid tumors, plus small‑molecule NR2F6 modulators, all in pre‑clinical or IND‑stage development.
Regen controls a portfolio of issued U.S. patents around NR2F6 modulation, cancer vaccines, and gene‑silencing technologies and monetizes some of this IP through licenses, notably to Zander Therapeutics for veterinary uses and to Oncology Pharma for human pancreatic and colon cancer indications, with upfront fees, royalties of 4–5% of Net Sales, and 10% of sublicense consideration. As of December 26, 2025, the company had 108,054,704 common shares outstanding and multiple preferred series, following a 1‑for‑1500 reverse split and a 2024 Series A preferred stock dividend, and continues to fund operations through Regulation A offerings, convertible notes, and share issuances for debt settlement and consulting services.
Regen BioPharma, Inc. filed an 8‑K disclosing unregistered sales of common stock. The company issued 6,800,000 shares on October 8, 2025 for $68,000 under a Tier 2 Regulation A offering sold directly by management.
On October 27, 2025, it issued 3,500,000 shares for $35,000 via Tier 2 Regulation A, and separately issued 4,500,000 shares to satisfy $30,204 of principal and $13,536 of accrued interest on convertible indebtedness under Section 4(a)(2), with no underwriters, commissions, or general solicitation.
On October 28, 2025, Regen issued 7,100,000 shares for $71,000 via Tier 2 Regulation A, and on November 10, 2025, it issued 1,780,000 shares for $17,800 via Tier 2 Regulation A. All Tier 2 Regulation A sales were conducted directly through management.
Regen BioPharma, Inc. disclosed that it raised cash through several unregistered sales of common stock to unaffiliated investors in mid-September
The shares were issued in reliance on Regulation A exemptions from registration under the Securities Act of 1933. No underwriters were involved, the sales were conducted directly by management without commissions or other consideration paid, and the company states that proceeds from each sale will be used for working capital.
Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class. The filing states Quick Capital has sole voting and sole dispositive power over all shares reported and identifies the filer as a Wyoming LLC with its business address in Miami, FL.
The statement is a passive Schedule 13G disclosure certifying the shares were not acquired to change or influence control of the issuer. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and no shared voting or dispositive powers are disclosed.
FAQ
What is the current stock price of Regen Biopharma (RGBPP)?
What is the market cap of Regen Biopharma (RGBPP)?
